Phase III readouts at lung cancer meetings underlined the competitive pressure in the ADC space. Gilead’s Trodelvy (sacituzumab govitecan) plus pembrolizumab failed to meet primary goals in the Evoke-03 study’s front-line NSCLC setting, raising the bar for next-generation TROP2 ADC strategies moving into earlier treatment lines. Separately, multiple data packages across lung cancer ADC development continued to show that survival benefits and response durability are increasingly scrutinized in first-line-adjacent trials. For biopharma teams, the key takeaway is that evidentiary thresholds for ADC combinations in earlier lines remain high, and sponsors may need clearer biomarkers or more convincing efficacy signals to justify label expansions beyond later-line use.